NIH-funded research NIH-funded research

A new therapeutic approach to help adults quit smoking

Official title: Translational Development of a Novel Therapeutic for Tobacco Dependence

Funded at Flik Therapeutics, INC. · NIH-11453254 · Data updated 2026-11-12

A new treatment being developed to help adults stop smoking, including young adults, using a novel therapeutic approach.

More Tobacco Dependence research and trials

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionFlik Therapeutics, INC.
NIH-funded
Lab location1 site (Philadelphia, United States)
Project startSeptember 15, 2026
Project endAugust 31, 2028
Funding year2026
Award (this year)$1,649,843
NIH project number1UG3DA067092-01
Project IDNIH-11453254 on NIH RePORTER

Who could benefit from this research

Could help

Adults 21 years and older who smoke or vape and are seeking to quit could be eligible for future participation.

Less likely to help

People who are not nicotine users or who cannot quit with this approach may not benefit.

What this research studies

This grant focuses on developing a new therapy to help people 21 and older quit nicotine addiction from cigarettes and e-cigarettes. It describes moving a potential treatment from early development toward something that could be tested in people. The work is conducted by Flik Therapeutics in Philadelphia and involves a translational plan to bring a promising therapy closer to patients who want to quit nicotine. The project outlines how the therapy will be tested for safety and effectiveness as part of a structured development timeline.

Why it matters

Potential benefit: If successful, this therapy could provide a new option to help people quit nicotine dependence more effectively.

How similar studies have gone: Previous smoking-cessation approaches have had limited success, making new therapies potentially impactful if proven effective.

Where this research is happening

  • Flik Therapeutics, INC.
    Philadelphia, United States
    Active

Researchers

  • Principal investigator: Heiden, Brendan — Flik Therapeutics, INC.
  • Study coordinator: Heiden, Brendan

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Browse more
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.